Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2025-12-26 @ 1:28 AM
Study NCT ID:
NCT05181033
Status:
RECRUITING
Last Update Posted:
2025-07-25
First Post:
2021-11-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Sponsor:
National University Hospital, Singapore
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-08
Completion Date Type:
ESTIMATED
First Submit Date:
2021-11-30
First Submit QC Date:
None
Study First Post Date:
2022-01-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-22
Last Update Post Date:
2025-07-25
Last Update Post Date Type:
ACTUAL